Journal of Virus Eradication最新文献

{"title":"ST2.1 – 00087 A Novel HIV-1 Immune Evasion Strategy: How Softer HIV-1 Infected cells Preferentially Resist Cytotoxic T Lymphocytes (CTLs)","authors":"L. Leyre, F. Mustapha, A. Herrera, M. Huse, R.B. Jones","doi":"10.1016/j.jve.2024.100446","DOIUrl":"10.1016/j.jve.2024.100446","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 35-36"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4.4 – 00091 Molecular Drivers of HIV-Induced Immune Modulation and CD8+ T Cell Dysfunction in Lymph Node Follicles during ART-Suppressed Subtype C Infection","authors":"Z. Ndhlovu, A. Papadopoulos, T. Khaba, T. Ngubane","doi":"10.1016/j.jve.2024.100415","DOIUrl":"10.1016/j.jve.2024.100415","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 14-15"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1.6 – 00161 HIV-1 Antisense Transcripts are frequent in FOXP3-negative Treglike cells expressing markers of persistence in vivo during acute HIV- 1 infection","authors":"M. Hale, G. Kundu, A. Geretz, P. Ehrenberg, R. Clifford, M. Robb, C. Sacdalan, S. Sriplienchan, N. Phanuphak, S. Vasan, R. Thomas, RV254 study team","doi":"10.1016/j.jve.2024.100399","DOIUrl":"10.1016/j.jve.2024.100399","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 4"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixation and reversion of mutations in the receptor-binding domain of the SARS-CoV-2 spike protein: A 2020–2024 analysis","authors":"Daniele Focosi , Pietro Giorgio Spezia , Fabrizio Maggi","doi":"10.1016/j.jve.2024.100581","DOIUrl":"10.1016/j.jve.2024.100581","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100581"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"8.5 – 00015 Changes in the composition of HIV-1 reservoir of PWH on ART and dasatinib","authors":"M. Manzanares, G. Casado-Fernández, A. Simón-Rueda, M. Torres, M. Coiras","doi":"10.1016/j.jve.2024.100440","DOIUrl":"10.1016/j.jve.2024.100440","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 31-32"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients","authors":"Jiayi Wang ,&nbsp;Lingyao Du ,&nbsp;Dongmei Zhang ,&nbsp;Chen Zhou ,&nbsp;Yilan Zeng ,&nbsp;Miao Liu ,&nbsp;Xing Cheng ,&nbsp;Xiaona Song ,&nbsp;Han Chen ,&nbsp;Ning Han ,&nbsp;Enqiang Chen ,&nbsp;Hong Tang","doi":"10.1016/j.jve.2024.100571","DOIUrl":"10.1016/j.jve.2024.100571","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.</div></div><div><h3>Methods</h3><div>In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China. Patients included adults with with CHC and any genotype (GT), with or without cirrhosis, hepatocellular carcinoma (HCC), HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection. Patients were administered SOF/VEL (400/100 mg) ± ribavirin (RBV) once daily for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12). Adverse events (AEs) were evaluated during treatment.</div></div><div><h3>Results</h3><div>The study included 483 patients with HCV genotypes 1, 2, 3, 6 and uncertain ones. Among them, 35.4 % (171/483, ITT) and 36.7 % (166/452, mITT) received SOF/VEL + RBV. At the end of treatment , 99.2 % (ITT, 479/483) and 99.1 % (mITT, 448/452) of patients had undetectable HCV RNA. SVR12 rates were 92.8 % [intention to treat (ITT), 448/483] and 99.1 % [modified ITT (mITT), 448/452]. In the mITT analysis, SVR12 for patients with HCV GT3b, those with cirrhosis or HCC, and those coinfected with HBV/HIV was 99.2 % (130/131), 99.4 % (168/169), and 97.6 % (40/41), respectively. The albumin-bilirubin (ALBI) (−3.01 <em>vs.</em> −3.18 <em>P</em> &lt; 0.001), Fibrosis-4 (FIB4) Index (2.53 <em>vs.</em> 1.88, <em>P</em> = 0.004) and AST to Platelet Ratio Index (APRI) (0.99 <em>vs.</em> 0.44, <em>P</em> &lt; 0.001) scores showed a significant decrease from baseline to SVR12. No patients experienced grade 3–5 AEs.</div></div><div><h3>Conclusions</h3><div>Although a high proportion of patients included in this study had HCV GT3b, cirrhosis, HCC, or HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection, SOF/VEL ± RBV was highly effective and well tolerated in Chinese patients with CHC.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100571"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial 10.4","authors":"","doi":"10.1016/j.jve.2024.100579","DOIUrl":"10.1016/j.jve.2024.100579","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100579"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP2.9 – 00007 HIV-PULSE as a newplatform to unveil HIV-1 reservoir composition: intactness, drug resistance, tropism and immune therapy predictions","authors":"S. De Braekeleer,&nbsp;L. Termote,&nbsp;S. Rutsaert,&nbsp;L. Lambrechts,&nbsp;W.A. Vos,&nbsp;A. Groenendijk,&nbsp;L. Van Eekeren,&nbsp;M. Blaauw,&nbsp;J. Stalenhoef,&nbsp;A. Verbon,&nbsp;M. Berrevoets,&nbsp;E. Blomme,&nbsp;M. Netea,&nbsp;A.J. Van Der Ven,&nbsp;S. Gerlo,&nbsp;L. Vandekerckhove","doi":"10.1016/j.jve.2024.100479","DOIUrl":"10.1016/j.jve.2024.100479","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 58"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6.1 – 00142 Durable Viral Load Remission in SHIV-infected Macaques after Vectored Delivery of Monoclonal Antibodies","authors":"J.M. Martinez-Navio,&nbsp;S.P. Fuchs,&nbsp;P.G. Mondragon,&nbsp;R. Zabizhin,&nbsp;D.E. Mendes,&nbsp;C.P.R. Muniz,&nbsp;K. Weisgrau,&nbsp;J. Furlott,&nbsp;E. Alexander,&nbsp;E.G. Rakasz,&nbsp;G. Gao,&nbsp;J.D. Lifson,&nbsp;R.C. Desrosiers","doi":"10.1016/j.jve.2024.100424","DOIUrl":"10.1016/j.jve.2024.100424","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 20-21"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP3.3 – 00121 Exploring the Effects of Benzodiazepines on a Novel Mechanism of Control in HIV-1 Infected Human Monocyte Derived Macrophages","authors":"C. Wallace,&nbsp;R. Van Duyne,&nbsp;P.J. Gaskill,&nbsp;Z. Klase","doi":"10.1016/j.jve.2024.100484","DOIUrl":"10.1016/j.jve.2024.100484","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 61-62"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}